AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie u.S. Retail Sales: Pharmacies and Drug Stores — Not Seasonally Adjusted ($M) ($M)
FRED (MRTSSM44611USN)
Latest, Q2 2026
97,059
Period ended Jun 30, 2026
Change on a year earlier
-2.8%
99,818 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
1
FRED (MRTSSM44611USN)
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. Retail Sales: Pharmacies and Drug Stores — Not Seasonally Adjusted ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 97,059 | -2.8% | FRED (MRTSSM44611USN) ↗ |
| Q1 2026 | Mar 31, 2026 | 93,047 | -3.0% | FRED (MRTSSM44611USN) ↗ |
| Q4 2025 | Dec 31, 2025 | 106,419 | +6.1% | FRED (MRTSSM44611USN) ↗ |
| Q3 2025 | Sep 30, 2025 | 102,171 | +6.7% | FRED (MRTSSM44611USN) ↗ |
| Q2 2025 | Jun 30, 2025 | 99,818 | +11.9% | FRED (MRTSSM44611USN) ↗ |
| Q1 2025 | Mar 31, 2025 | 95,892 | +10.2% | FRED (MRTSSM44611USN) ↗ |
| Q4 2024 | Dec 31, 2024 | 100,312 | +9.1% | FRED (MRTSSM44611USN) ↗ |
| Q3 2024 | Sep 30, 2024 | 95,792 | +12.6% | FRED (MRTSSM44611USN) ↗ |
| Q2 2024 | Jun 30, 2024 | 89,173 | +5.3% | FRED (MRTSSM44611USN) ↗ |
| Q1 2024 | Mar 31, 2024 | 86,987 | +6.3% | FRED (MRTSSM44611USN) ↗ |
| Q4 2023 | Dec 31, 2023 | 91,914 | +10.0% | FRED (MRTSSM44611USN) ↗ |
| Q3 2023 | Sep 30, 2023 | 85,089 | +5.4% | FRED (MRTSSM44611USN) ↗ |
| Q2 2023 | Jun 30, 2023 | 84,702 | +5.6% | FRED (MRTSSM44611USN) ↗ |
| Q1 2023 | Mar 31, 2023 | 81,848 | +4.2% | FRED (MRTSSM44611USN) ↗ |
| Q4 2022 | Dec 31, 2022 | 83,522 | +1.4% | FRED (MRTSSM44611USN) ↗ |
| Q3 2022 | Sep 30, 2022 | 80,759 | +2.9% | FRED (MRTSSM44611USN) ↗ |
| Q2 2022 | Jun 30, 2022 | 80,205 | +3.1% | FRED (MRTSSM44611USN) ↗ |
| Q1 2022 | Mar 31, 2022 | 78,562 | +6.1% | FRED (MRTSSM44611USN) ↗ |
| Q4 2021 | Dec 31, 2021 | 82,362 | +7.8% | FRED (MRTSSM44611USN) ↗ |
| Q3 2021 | Sep 30, 2021 | 78,463 | +6.4% | FRED (MRTSSM44611USN) ↗ |
| Q2 2021 | Jun 30, 2021 | 77,815 | +9.6% | FRED (MRTSSM44611USN) ↗ |
| Q1 2021 | Mar 31, 2021 | 74,074 | +0.2% | FRED (MRTSSM44611USN) ↗ |
| Q4 2020 | Dec 31, 2020 | 76,397 | +5.5% | FRED (MRTSSM44611USN) ↗ |
| Q3 2020 | Sep 30, 2020 | 73,730 | +6.0% | FRED (MRTSSM44611USN) ↗ |
| Q2 2020 | Jun 30, 2020 | 71,004 | -0.3% | FRED (MRTSSM44611USN) ↗ |
| Q1 2020 | Mar 31, 2020 | 73,896 | +5.3% | FRED (MRTSSM44611USN) ↗ |
| Q4 2019 | Dec 31, 2019 | 72,429 | 0.0% | FRED (MRTSSM44611USN) ↗ |
| Q3 2019 | Sep 30, 2019 | 69,577 | +2.3% | FRED (MRTSSM44611USN) ↗ |
| Q2 2019 | Jun 30, 2019 | 71,198 | +3.8% | FRED (MRTSSM44611USN) ↗ |
| Q1 2019 | Mar 31, 2019 | 70,148 | +3.3% | FRED (MRTSSM44611USN) ↗ |
| Q4 2018 | Dec 31, 2018 | 72,395 | +2.5% | FRED (MRTSSM44611USN) ↗ |
| Q3 2018 | Sep 30, 2018 | 68,000 | +2.5% | FRED (MRTSSM44611USN) ↗ |
| Q2 2018 | Jun 30, 2018 | 68,605 | +2.5% | FRED (MRTSSM44611USN) ↗ |
| Q1 2018 | Mar 31, 2018 | 67,924 | +4.9% | FRED (MRTSSM44611USN) ↗ |
| Q4 2017 | Dec 31, 2017 | 70,632 | +7.0% | FRED (MRTSSM44611USN) ↗ |
| Q3 2017 | Sep 30, 2017 | 66,360 | +2.2% | FRED (MRTSSM44611USN) ↗ |
| Q2 2017 | Jun 30, 2017 | 66,915 | +1.5% | FRED (MRTSSM44611USN) ↗ |
| Q1 2017 | Mar 31, 2017 | 64,752 | -1.4% | FRED (MRTSSM44611USN) ↗ |
| Q4 2016 | Dec 31, 2016 | 66,029 | – | FRED (MRTSSM44611USN) ↗ |
| Q3 2016 | Sep 30, 2016 | 64,902 | – | FRED (MRTSSM44611USN) ↗ |
| Q2 2016 | Jun 30, 2016 | 65,939 | – | FRED (MRTSSM44611USN) ↗ |
| Q1 2016 | Mar 31, 2016 | 65,685 | – | FRED (MRTSSM44611USN) ↗ |
Cite this data
StockData. (2026). AbbVie U.S. Retail Sales: Pharmacies and Drug Stores — Not Seasonally Adjusted ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fred_rx_retail_nsa
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.